Related Experiment Video

Updated: Apr 15, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

[Second generation ALK inhibitors in non-small cell lung cancer: systemic review]

Marie Viala1, Solenn Brosseau2, David Planchard3

  • 1Institut Gustave-Roussy, département d'innovation thérapeutique et d'essais précoces, 94805 Villejuif, France; CHU de Clermont-Ferrand, oncologie médicale, 63011 Clermont-Ferrand, France.

Bulletin Du Cancer
|March 31, 2015
PubMed

Insights

The EML4-ALK rearrangement drives non-small cell lung cancer (NSCLC), initially treated with crizotinib. Acquired resistance necessitates exploring newer, second-generation ALK inhibitors for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The EML4-ALK fusion gene is identified in 5% of non-small cell lung cancer (NSCLC) cases.
  • First-generation anaplastic lymphoma kinase (ALK) inhibitors like crizotinib show efficacy but face acquired resistance.
  • Resistance mechanisms include ALK gene mutations (e.g., L1196M), amplification, and activation of bypass pathways (EGFR, KRAS).

Purpose of the Study:

  • To review the development and efficacy of second-generation ALK inhibitors.
  • To summarize ongoing clinical trial results for novel ALK inhibitors.
  • To discuss optimal treatment strategies for ALK-positive (ALK+) NSCLC.

Main Methods:

  • Literature review of clinical trials and research on ALK inhibitors in NSCLC.
  • Analysis of resistance mechanisms to first-generation ALK inhibitors.
  • Comparison of efficacy and safety profiles of second-generation ALK inhibitors.

Main Results:

  • Second-generation ALK inhibitors (ceritinib, alectinib, AP26113) have been developed to overcome resistance.
  • Ongoing trials are evaluating the efficacy and safety of these novel agents.
  • These inhibitors aim to provide durable responses in patients with acquired resistance.

Conclusions:

  • Second-generation ALK inhibitors represent a significant advancement in treating ALK+ NSCLC.
  • Understanding resistance mechanisms is crucial for selecting appropriate therapies.
  • Personalized treatment approaches are essential for managing advanced ALK+ NSCLC.
Keywords:
ALKALK inhibitorsCancer bronchique non à petites cellulesCrizotinibInhibiteurs de ALKMécanismes de résistanceNSCLCResistance mechanisms

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

547

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.8K